Calumet Consensus Price Target Raised by 15.62% to $56.61
The average one-year price target for Calumet (NASDAQGS:CLMT) has been revised to $56.61 / share. This is an increase of 15.62% from the prior estimate of $48.96 dated August 25, 2026. These figures represent aggregate analyst targets compiled by Fintel, rather than a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $40.40 to a high of $78.75 / share. The average price target represents an increase of 0.11% from the latest reported closing price of $56.55 / share on September 14, 2026. The current target range width of $38.35 represents a widening of +69.69% from the prior target range width of $22.60.
As of September 11, 2026, the current median target is $54.57, which increased from the prior median of $46.92. Looking at the target history, the mean target was $56.61 on September 15, 2026, $48.96 on August 28, 2026, and $40.29 on both August 5, 2026, and July 1, 2026. The observed twelve-month high mean target was $56.61 on September 15, 2026, while the observed twelve-month low mean target was $19.12 on February 4, 2026. This represents 2 consecutive target revisions in the increased direction.
For context, Calumet's stock price changed by +6.44% over one week, from a baseline close of $53.13 on September 4, 2026. Over one month, the price changed by +18.50% from a baseline close of $47.72 on August 14, 2026. In its latest earnings report on August 7, 2026, Calumet reported actual EPS of -1.09, compared to an estimate of 0.102, representing a surprise of -1,168.63%. Actual revenue was $1,445,100,000.00, which was +30.98% above the estimated $1,103,307,225.00.
Calumet operates in the Materials sector, specifically the Specialty Chemicals sub-industry. Within this sub-industry, 15 companies are covered, with 4 raised, 2 lowered, and 9 unchanged. The sub-industry median revision percent is 0.00%, and the median implied change percent is +30.12%. Analyst recommendations as of September 1, 2026, show a total of 12 recommendations, with 58.3% positive and 41.7% hold. Recent rating actions include HC Wainwright & Co. maintaining a Buy grade on September 2, 2026, UBS maintaining a Neutral grade on August 25, 2026, and Goldman Sachs maintaining a Neutral grade on August 18, 2026.
Among its peers in the specialty lubricants and chemical space, target revisions ranged from a slight decrease to a minor increase, while implied changes varied widely.
| Company | Target revision | Implied change |
|---|---|---|
| HF Sinclair Corporation - Corporate Bond | +1.24% | -15.79% |
| Valvoline | -0.23% | +46.18% |
| Quaker Chemical | 0.00% | +27.80% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.